• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Venus Concept Inc.

    6/12/25 4:19:19 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    DEFA14A 1 ef20050557_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 14A
     
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

    Filed by the Registrant ☒
    Filed by a party other than the Registrant  ☐
     
    Check the appropriate box:
      ☐
    Preliminary Proxy Statement
      ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
      ☐
    Definitive Proxy Statement
      ☒
    Definitive Additional Materials
      ☐
    Soliciting Material Under §240.14a-12
     
    Venus Concept Inc.
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     
    Payment of Filing Fee (Check the appropriate box):
      ☒
    No fee required.
      ☐
    Fee paid previously with preliminary materials.
      ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



    SUPPLEMENT TO PROXY STATEMENT FOR THE 2025 ANNUAL AND SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 25, 2025
     
    Explanatory Note
     
    On April 30, 2025, Venus Concept Inc., a Delaware corporation (the “Company”), filed a definitive proxy statement (the “Proxy Statement”) relating to the Company’s Annual and Special Meeting of Stockholders to be held on Wednesday, June 25, 2025, at 8:00 a.m. Eastern Daylight Time (the “Meeting”). You will be able to attend and participate in the Meeting online by visiting www.virtualshareholdermeeting.com/VERO2025. As previously disclosed, the record date for determining the Company’s stockholders entitled to vote at the Meeting was fixed as of the close of business on April 28, 2025.
     
    The Meeting is being held for the purposes set forth in the Proxy Statement, as supplemented and amended by this supplement (this “Supplement”). Capitalized terms not defined in this Supplement have the meanings set forth in the Proxy Statement.
     
    Background
     
    As previously disclosed in the Company’s Exchange Act filings, pursuant to an Exchange Agreement, dated March 31, 2025, among the Company and certain investors, such investors exchanged (the “2025 Exchange”) Secured Subordinated Convertible Notes issued by the Company, dated October 4, 2023, with an aggregate outstanding balance of $28,015,827.33 (the “Old Notes”), for (among other consideration) replacement Secured Subordinated Convertible Notes issued by the Company, dated March 31, 2025, with an aggregate original principal amount of $17,015,808.33 (the “New Notes”).
     
    The New Notes are identical to the Old Notes, except for (i) the reduction in the outstanding balance on account of the 2025 Exchange, (ii) the addition of a minimum liquidity covenant requiring that the Company maintain an average daily deposit balance in investor-controlled accounts of at least $3,000,000, measured monthly and (iii) certain other immaterial changes.
     
    Supplement
     
    The Proxy Statement states that Proposal No. 6 is for the following purpose:
     
    To approve, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 64,454 shares of common stock of the Company upon the conversion of the Convertible Promissory Note issued by the Company on October 4, 2023, as amended (the “October 2023 Convertible Note”) (the proposal being, the “October 2023 Convertible Note Proposal”)
     
    This Supplement is intended to clarify that the terms “October 2023 Convertible Note” or “October 2023 Convertible Notes,” as used in the Proxy Statement, are intended to encompass the New Notes issued in the 2025 Exchange. The other aspects of Proposal No. 6, including the number of shares of common stock of the Company that would become issuable under Nasdaq Listing Rule 5635(b) upon approval of Proposal No. 6, are unchanged.
     
    Based on the foregoing, the existing description of Proposal No. 6 that appears in the Notice of Annual and Special Meeting of Stockholders in the front of the Proxy Statement is hereby amended and replaced in its entirety as follows:
     
    To approve, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 64,454 shares of common stock of the Company upon the conversion of the Secured Subordinated Convertible Notes issued by the Company on March 31, 2025 (the “October 2023 Convertible Notes”) (the proposal being, the “October 2023 Convertible Notes Proposal”)
     

    Based on the foregoing, the existing “Background” section that appears in Proposal No. 6 (beginning on page 18 of the Proxy Statement) is hereby amended and replaced in its entirety as follows:
     
    Background
     
    Exchange Transaction
     
    As previously disclosed, pursuant to an Exchange Agreement, dated March 31, 2025, among the Company and certain investors, such investors exchanged Secured Subordinated Convertible Notes issued by the Company, dated October 4, 2023, with an aggregate outstanding balance of $28,015,827.33, for (among other consideration) replacement Secured Subordinated Convertible Notes issued by the Company, dated March 31, 2025, with an aggregate original principal amount of $17,015,808.33 (the “October 2023 Convertible Notes”).
     
    As previously disclosed, we granted customary resale registration rights with respect to the shares of common stock issuable upon conversion of the October 2023 Convertible Notes.
     
    Terms of October 2023 Convertible Notes
     
    At any time prior to the maturity date, the holders may elect to convert the October 2023 Convertible Notes into shares of our common stock at the then applicable conversion rate. The current conversion rate is 3.78788 shares of common stock per $1,000 principal amount of October 2023 Convertible Notes, which represents a conversion price of $264 per share of common stock. The conversion rate is subject to customary adjustments upon the occurrence of certain events.
     
    The October 2023 Convertible Notes accrue interest at a rate of 3-month adjusted term Secured Overnight Financing Rate (SOFR) plus 8.50% per annum. In the case of an event of default under the October 2023 Convertible Notes, the then-applicable interest rate will increase by four percent (4.00)% per annum. Interest is payable in kind in arrears on the last business day of each calendar quarter of each year after the original issuance date. The October 2023 Convertible Notes mature on December 9, 2026, unless earlier redeemed or converted.
     
    Based on the foregoing, the first paragraph of the existing “Reasons for the Proposal” section that appears in Proposal No. 6 (beginning on page 18 of the Proxy Statement) is hereby amended and replaced in its entirety as follows:
     
    We are required to seek stockholder approval of this Proposal No. 6 under the terms of the Exchange Agreement described above. At the recommendation of our Board, we pursued the exchange transaction as part of a larger debt restructuring initiative that commenced in 2024. We undertook such initiative to reduce our debt, thereby strengthening our balance sheet, and to cure a listing deficiency on the Nasdaq Capital Market relating to our total stockholders’ equity. The initiative, of which the exchange transaction formed a critical part, reduced our outstanding debt by approximately $50 million and cured such listing deficiency.
     
    Except as set forth above, the Proxy Statement remains unchanged.
     
    THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL NO. 6 TO APPROVE THE ISSUANCE OF UP TO 64,454 SHARES OF COMMON STOCK UPON CONVERSION OF THE OCTOBER 2023 CONVERTIBLE NOTES.
     
    This Supplement does not provide all of the information that is important to your decisions in voting at the Meeting. Accordingly, we encourage you to carefully read this Supplement, together with the Proxy Statement, when considering how to vote at the Meeting.
     
    Whether you plan to attend the Meeting, we encourage you to submit your proxy or voting instructions as soon as possible. If you have already returned your proxy card or provided voting instructions to your broker, you do not need to take any action unless you wish to change your vote.
     


    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share. In a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that are immediately exercisable upon issuance and will expire eighteen months following the effective date of the registration statement cov

      6/9/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Venus Concept Inc.

      SCHEDULE 13G - Venus Concept Inc. (0001409269) (Subject)

      6/13/25 5:31:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Venus Concept Inc.

      DEFA14A - Venus Concept Inc. (0001409269) (Filer)

      6/12/25 4:19:19 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Venus Concept Inc.

      SCHEDULE 13G/A - Venus Concept Inc. (0001409269) (Subject)

      6/11/25 4:05:18 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care